Literature DB >> 1826617

Effects of acute paroxetine administration on tryptophan metabolism and disposition in the rat.

A A Badawy1, C J Morgan.   

Abstract

1 The effects of acute oral administration of paroxetine on tryptophan metabolism and disposition were examined in the rat. 2 Basal liver tryptophan pyrrolase activity was inhibited by paroxetine in vitro and after oral administration. Maximum inhibition was caused by a 1 mg kg-1 dose. 3 Paroxetine administration also inhibited pyrrolase activity that had previously been enhanced by hormonal induction by cortisol or cofactor activation by haematin. The cortisol induction of the enzyme was, however, not inhibited by pretreatment of rats with paroxetine. 4 Paroxetine increased tryptophan availability to the brain, because of the above pyrrolase-inhibitory mechanism. Cerebral 5-hydroxytryptamine (5-HT) synthesis was accordingly enhanced, though this was apparent only with doses of the drug of up to 1 mg kg-1. With larger doses, decreased 5-HT turnover, probably as a result of 5-HT uptake inhibition, was the more dominant feature. 5 Paroxetine lowered circulating corticosterone concentration, but did not influence those of albumin, non-esterified fatty acids or glucose. 6 It is concluded that, in addition to inhibiting brain 5-HT turnover, paroxetine also, in common with 20 other antidepressants, enhances 5-HT synthesis by increasing brain tryptophan concentration secondarily to inhibition of liver tryptophan pyrrolase activity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1826617      PMCID: PMC1918012          DOI: 10.1111/j.1476-5381.1991.tb12190.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

1.  Regulation of rat liver tryptophan pyrrolase by its cofactor haem: Experiments with haematin and 5-aminolaevulinate and comparison with the substrate and hormonal mechanisms.

Authors:  A A Badawy; M Evans
Journal:  Biochem J       Date:  1975-09       Impact factor: 3.857

2.  Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor.

Authors:  D R Thomas; D R Nelson; A M Johnson
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

3.  Effect of an uptake inhibitor on serotonin metabolism in rat brain: studies with 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine (Lilly 110140).

Authors:  R W Fuller; K W Perry; B B Molloy
Journal:  Life Sci       Date:  1974-09-15       Impact factor: 5.037

4.  High-fat diets increase tryptophan availability to the brain: importance of choice of the control diet.

Authors:  A A Badawy; C J Morgan; N R Davis; A Dacey
Journal:  Biochem J       Date:  1984-02-01       Impact factor: 3.857

5.  Paroxetine in the treatment of depression: a comparison with imipramine and placebo.

Authors:  J P Feighner; W F Boyer
Journal:  Acta Psychiatr Scand Suppl       Date:  1989

6.  A placebo-controlled, double-blind, clinical trial of paroxetine in depressed outpatients.

Authors:  K Rickels; J Amsterdam; C Clary; I Fox; E Schweizer; C Weise
Journal:  Acta Psychiatr Scand Suppl       Date:  1989

7.  Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan.

Authors:  P L Delgado; D S Charney; L H Price; G K Aghajanian; H Landis; G R Heninger
Journal:  Arch Gen Psychiatry       Date:  1990-05

8.  The pharmacologic profile of fluoxetine.

Authors:  P Stark; R W Fuller; D T Wong
Journal:  J Clin Psychiatry       Date:  1985-03       Impact factor: 4.384

9.  Paroxetine in the treatment of depression--a randomized comparison with amitriptyline.

Authors:  A L Laursen; P L Mikkelsen; S Rasmussen; P le Fèvre Honoré
Journal:  Acta Psychiatr Scand       Date:  1985-03       Impact factor: 6.392

10.  Inhibition of rat liver tryptophan pyrrolase activity and elevation of brain tryptophan concentration by acute administration of small doses of antidepressants.

Authors:  A A Badawy; M Evans
Journal:  Br J Pharmacol       Date:  1982-09       Impact factor: 8.739

View more
  4 in total

1.  Combined Pharmacotherapy and Cognitive-Behavioral Therapy for Anxiety Disorders: Medication Effects, Glucocorticoids, and Attenuated Treatment Outcomes.

Authors:  Michael W Otto; R Kathryn McHugh; Kathleen M Kantak
Journal:  Clin Psychol (New York)       Date:  2010-06-08

2.  Tryptophan, Neurodegeneration and HIV-Associated Neurocognitive Disorder.

Authors:  Nicholas W S Davies; Gilles Guillemin; Bruce J Brew
Journal:  Int J Tryptophan Res       Date:  2010-06-10

3.  Neuroimmune endocrine effects of antidepressants.

Authors:  Marco Antonioli; Joanna Rybka; Livia A Carvalho
Journal:  Neuropsychiatr Dis Treat       Date:  2012-02-07       Impact factor: 2.570

4.  Chronic citalopram administration causes a sustained suppression of serotonin synthesis in the mouse forebrain.

Authors:  Gerard Honig; Minke E Jongsma; Marieke C G van der Hart; Laurence H Tecott
Journal:  PLoS One       Date:  2009-08-27       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.